Biotech Breakthrough: VarmX Set to Showcase Innovative Solutions for Anticoagulation Reversal at Major European Events

VarmX Announces Plans to Attend LSX World Congress and Bio€quity Europe in Q2 2024

VarmX, a biotech company that is dedicated to developing innovative solutions for reversing anticoagulation, has announced that it will be attending two major events in Europe. The company will participate in the LSX World Congress on April 29-30 and present at Bio€quity Europe on May 12-14.

The LSX World Congress is a prominent partnering, strategy, and investment event in Europe that offers 1:1 partnering opportunities. VarmX will attend the event to engage with investors and other biopharmaceutical companies. Martijn Negen, VarmX’s SVP Global Commercial Strategy & Business Development, will also participate in a panel discussion at the event.

Bio€quity Europe, organized by BioCentury, is a key biopartnering event for the European biotech industry. Martijn Negen has been selected to present at this prestigious event. If you wish to meet with the VarmX Team at either of these upcoming events or obtain more information, please contact

VarmX is a spin-off from Leiden University Medical Center (LUMC) that was founded in 2016 by Professor Pieter Reitsma, an expert in hemostasis and thrombosis. The company’s lead compound VMX-C001 is a modified recombinant blood factor X developed for treating severe spontaneous bleeding and preventing bleeding during urgent surgeries in patients using oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. VarmX is backed by a strong group of investors including Sound Bioventures, EIC, EQT Life Sciences (formerly LSP), Inkef, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures

Leave a Reply